Previous close | 0.7400 |
Open | 0.7400 |
Bid | 0.0000 |
Ask | 4.5000 |
Strike | 205.00 |
Expiry date | 2023-03-17 |
Day's range | 0.7400 - 0.7400 |
Contract range | N/A |
Volume | |
Open interest | 7 |
Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day.
TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI™), an anti-amyloid-β (Aβ) protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Minis
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.